Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $1.48 million for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Performance

Shares of TSHA traded down $0.21 during trading hours on Tuesday, reaching $2.26. 862,544 shares of the company's stock traded hands, compared to its average volume of 2,216,919. The firm has a market capitalization of $462.40 million, a price-to-earnings ratio of 3.58 and a beta of 0.90. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The business's fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.81. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $4.32.

Analyst Upgrades and Downgrades

TSHA has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. JMP Securities restated a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Cantor Fitzgerald restated an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.